TNXP - רווח נקי למניה (EPS TTM) Tonix Pharma

Tonix Pharmaceuticals profitability is vulnerable due to global supply chain complexities and patent disputes. The company's TTM net income per share reflects the impact of external factors, where -12.25 represents the latest metric reading. A lack of stable cash flows leaves the biotech firm dependent on investment, forcing management to implement restructuring and focus on final-stage trials to preserve liquidity.
Tonix Pharmaceuticals Holding (TNXP) - פילוחי מדדים ודוחות פיננסיים

This indicator calculates the rolling net income per share over the last four quarters, allowing investors to assess the actual return on equity while stripping out reporting period volatility. By analyzing the EPS TTM fundamental metric, one can track how the costs of developing drugs for neurological disorders and the attraction of investment impact the final shareholder value in Tonix Pharmaceuticals (TNXP).